Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-2755-2026

FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21M402, IFU Reference Number LBL1062

Publicado el 29 de julio de 2026 · Inicio del retiro: 11 de junio de 2026

Resumen

FDA registra el retiro Z-2755-2026 de dispositivos médicos de Clase II, publicado el 29 de julio de 2026 e iniciado el 11 de junio de 2026. Empresa responsable: Boston Scientific Corporation; Estado: En curso; Cantidad reportada: 74,760 units; Lote: UDI-DI: 00810087180072; Lots: CL12697, CL12698, CL12701, CL12702, CL12824, CL12832, CL12833, CL12861, CL12888, CL12889, CL12912, CL12913, CL12916, CL12918, CL12968, CL12975, CL12977, CL13003, CL13016, CL13019, CL13045, CL13047, CL13059, CL13078, CL13079, CL13101, CL13102, CL13120, CL13121, CL13140, CL13141, CL13158, CL13159, CL13195, CL13211, CL13218, CL13232, CL13233, CL13259, CL13290, CL13339, CL13367, CL13400, CL13421, CL13516, CL13518, CL13572, CL13577, CL13615, CL13645, CL13669, CL13707, CL13720, CL13733, CL13821, CL13834, CL13857, CL13926, CL13941, CL13976, CL13989, CL14026, CL14052, CL14078, CL14121, CL14138, CL14170, CL14186, CL14225, CL14248, CL14285, CL14344, CL14352, CL14374, CL14395, CL14438, CL14487, CL14499, CL14517, CL14580, CL14632, CL14669, CL14690, CL14710, CL14748, CL14768, CL14967, CL15004, CL15008, CL15066, CL15106, CL15127, CL15190, CL15238, CL15271, CL15317, CL15357, CL15396, CL15426, CL15473, CL15489, CL15567, CL15636, CL15639, CL15753, CL15774, CL15807. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.

Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Boston Scientific Corporation
Distribuidor
Global Distribution. US Nationwide.
Lote
UDI-DI: 00810087180072; Lots: CL12697, CL12698, CL12701, CL12702, CL12824, CL12832, CL12833, CL12861, CL12888, CL12889, CL12912, CL12913, CL12916, CL12918, CL12968, CL12975, CL12977, CL13003, CL13016, CL13019, CL13045, CL13047, CL13059, CL13078, CL13079, CL13101, CL13102, CL13120, CL13121, CL13140, CL13141, CL13158, CL13159, CL13195, CL13211, CL13218, CL13232, CL13233, CL13259, CL13290, CL13339, CL13367, CL13400, CL13421, CL13516, CL13518, CL13572, CL13577, CL13615, CL13645, CL13669, CL13707, CL13720, CL13733, CL13821, CL13834, CL13857, CL13926, CL13941, CL13976, CL13989, CL14026, CL14052, CL14078, CL14121, CL14138, CL14170, CL14186, CL14225, CL14248, CL14285, CL14344, CL14352, CL14374, CL14395, CL14438, CL14487, CL14499, CL14517, CL14580, CL14632, CL14669, CL14690, CL14710, CL14748, CL14768, CL14967, CL15004, CL15008, CL15066, CL15106, CL15127, CL15190, CL15238, CL15271, CL15317, CL15357, CL15396, CL15426, CL15473, CL15489, CL15567, CL15636, CL15639, CL15753, CL15774, CL15807
Clasificación de riesgo
Class II
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21M402, IFU Reference Number LBL1062 fue retirado del mercado?

Sí. FDA publicó el retiro Z-2755-2026 el 29 de julio de 2026. Peligro reportado: Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter